Search clinical trials for: MEDI6469

Total 5 results

MedImmune LLC

Terminated

A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies (MEDI6469)

Advanced Solid Tumors | Aggressive B-cell Lymphomas

United States
Providence Health & Services
MedImmune LLC; Providence Cancer Center, Earle A. Chiles Research Institute; Robert...

Completed

Stereotactic Body Radiation and Monoclonal Antibody to OX40 (MEDI6469) in Breast Cancer Patients With Metastatic Lesions (OX40 Breast)

Metastatic Breast Cancer | Lung Metastases | Liver Metastases

United States
Providence Health & Services
MedImmune LLC

Terminated

Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer

Colorectal Neoplasms

United States
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40 Antibody in Head and Neck Cancer Patients

Head and Neck Cancer

United States
Providence Health & Services
MedImmune LLC

Completed

Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer

Prostate Cancer | Metastatic Prostate Cancer | Cancer of the Prostate

United States

3

Subscribe